Misplaced Pages

Nepafenac: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 08:55, 10 August 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChEBI_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors or [[user← Previous edit Revision as of 06:30, 1 September 2011 edit undoBogBot (talk | contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBotNext edit →
Line 1: Line 1:
{{drugbox {{Drugbox
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0J9L7J6V8C
| verifiedrevid = 444023214 | verifiedrevid = 444023214
| IUPAC_name = 2-amino-3-benzoylbenzeneacetamide | IUPAC_name = 2-amino-3-benzoylbenzeneacetamide
| image = Nepafenac-2D-skeletal.png | image = Nepafenac-2D-skeletal.png

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
<!--Clinical data-->
| ChemSpiderID = 133160
| tradename =
| InChI = 1/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
| Drugs.com = {{drugs.com|monograph|nepafenac}}
| InChIKey = QEFAQIPZVLVERP-UHFFFAOYAP
| MedlinePlus = a606007
| smiles = O=C(c1cccc(c1N)CC(=O)N)c2ccccc2
| pregnancy_category = C
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1021 | legal_US = Rx-only
| legal_status =
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| routes_of_administration = ]
| StdInChI = 1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
<!--Pharmacokinetic data-->
| StdInChIKey = QEFAQIPZVLVERP-UHFFFAOYSA-N
| CAS_number = | bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =

<!--Identifiers-->
| CAS_number =
| ATC_prefix = S01 | ATC_prefix = S01
| ATC_suffix = BC10 | ATC_suffix = BC10
| ATC_supplemental = | ATC_supplemental =
| PubChem = 151075 | PubChem = 151075
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06802 | DrugBank = DB06802
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 133160
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0J9L7J6V8C
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05143 | KEGG = D05143
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| C = 15 |H = 14 |N = 2 |O = 2
| ChEMBL = 1021

<!--Chemical data-->
| C=15 | H=14 | N=2 | O=2
| molecular_weight = 254.28 ]/] | molecular_weight = 254.28 ]/]
| smiles = O=C(c1cccc(c1N)CC(=O)N)c2ccccc2
| bioavailability =
| InChI = 1/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
| protein_bound =
| InChIKey = QEFAQIPZVLVERP-UHFFFAOYAP
| metabolism =
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| elimination_half-life =
| StdInChI = 1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
| pregnancy_category = C
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| legal_US = Rx-only
| StdInChIKey = QEFAQIPZVLVERP-UHFFFAOYSA-N
| legal_status =
| routes_of_administration = ]
}} }}



Revision as of 06:30, 1 September 2011

Pharmaceutical compound
Nepafenac
Clinical data
AHFS/Drugs.comMonograph
MedlinePlusa606007
Pregnancy
category
  • C
Routes of
administration
Ophthalmic
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • 2-amino-3-benzoylbenzeneacetamide
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.207.414 Edit this at Wikidata
Chemical and physical data
FormulaC15H14N2O2
Molar mass254.28 g/mol g·mol
3D model (JSmol)
SMILES
  • O=C(c1cccc(c1N)CC(=O)N)c2ccccc2
InChI
  • InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
  • Key:QEFAQIPZVLVERP-UHFFFAOYSA-N
  (verify)

Nepafenac is a non-steroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop (0.1% solution. Nepafenac is manufactured by Alcon as Nevanac. It is used to treat pain and inflammation associated with cataract surgery.

The usual dose is 1 drop in each affected eye beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period.

Its side effects may include decreased visual acuity, a feeling that something is in the eye, increased eye pressure or a sticky sensation, as well as other effects.

External links

Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)
pyrazolones /
pyrazolidines
salicylates
acetic acid derivatives
and related substances
oxicams
propionic acid
derivatives (profens)
n-arylanthranilic
acids (fenamates)
COX-2 inhibitors
(coxibs)
other
NSAID
combinations
Key: underline indicates initially developed first-in-class compound of specific group; WHO-Essential Medicines; withdrawn drugs; veterinary use.
Category:
Nepafenac: Difference between revisions Add topic